Statins in oncological research: From experimental studies to clinical practice

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 3, 2014, Pages 296-311

  Kubatka, Peter ^a   Kruzliak, Peter ^b   Rotrekl, Vladimir ^b   Jelinkova, Sarka ^b   Mladosievicova, Beata ^c  

^a Jessenius Faculty of Medicine in Martin and University Hospital Martin   (Slovakia)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c St Anne's University Hospital ^*  (Slovakia)

Author keywords

Anti tumor properties; Cancer risk reduction; Cancer therapy; Carcinogenesis; Chemoprevention; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BARRETT ESOPHAGUS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER MORTALITY; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER STEM CELL; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; ESOPHAGUS CANCER; EXPERIMENTAL STUDY; HUMAN; LIVER CELL CARCINOMA; LIVER TOXICITY; METASTASIS INHIBITION; NONHUMAN; RAT MODEL; REVIEW; ANIMAL; DISEASE MODEL; DRUG SCREENING; MEDICAL RESEARCH; MORTALITY; NEOPLASMS; RISK;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS; RISK;

EID: 84912100863     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.08.002     Document Type: Review

References (135)

1. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109:III-39-III-43.
2. Anderson T.J., Meredith I.T., Yeung A.C., et al. The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995, 332:488-493.
3. Feron O., Dessy C., Desager J.P., et al. Hydroxymethylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001, 103:113-118.
4. Wenger N.K. Prevention of cardiovascular disease: highlights for the clinician of the 2013 American College of Cardiology/American Heart Association guidelines. Clin Cardiol 2014, 37:239-251.
5. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013, 1:CD004816.
6. Minder C.M., Blumenthal R.S., Blaha M.J. Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. Curr Opin Cardiol 2013, 28:554-560.
7. Campbell M.J., Esserman L.J., Zhou Y., et al. Breast cancer growth prevention by statins. Cancer Res 2006, 66:8707-8714.
8. Cafforio P., Dammacco F., Gernone A., Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005, 26:883-891.
9. Kato S., Smalley S., Sadarangani A., et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med 2010, 14:1180-1193.
10. Wong W.W., Tan M.M., Xia Z., et al. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 2001, 7:2067-2075.
11. Howe K., Sanat F., Thumser A.E., et al. The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes. Xenobiotica 2011, 41:519-529.
12. Dimitroulakos J., Ye L.Y., Benzaquen M., et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 2001, 7:158-167.
13. Murakami M., Goto T., Saito Y., et al. The inhibitory effect of simvastatin on growth in malignant gliomas with special reference to its local application with fibrin glue spray in vivo. Int J Oncol 2001, 19:525-531.
14. Novak A., Binnington B., Ngan B., et al. Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies. Glycobiology 2013, 23:1230-1239.
15. Osmak M. Statins and cancer: current and future prospects. Cancer Lett 2012, 324:1-12.
16. Crick D.C., Andres D.A., Danesi R., et al. Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J Neurochem 1998, 70:2397-2405.
17. Buchwald H. Cholesterol inhibition, cancer and chemotherapy. Lancet 1992, 39:1154-1156.
18. Liang Y.W., Chang C.C., Hung C.M., et al. Preclinical activity of simvastatin induces cell cycle arrest in G1 via blockade of cyclin D-Cdk4 expression in non-small cell lung cancer (NSCLC). Int J Mol Sci 2013, 14:5806-5816.
19. Zeybek N.D., Gulcelik N.E., Kaymaz F.F., et al. Rosuvastatin induces apoptosis in cultured human papillary thyroid cancer cells. J Endocrinol 2011, 210:105-115.
20. Wu W.C., Lai Y.H., Hsieh M.C., et al. Pleiotropic role of atorvastatin in regulation of human retinal pigment epithelial cell behaviours in vitro. Exp Eye Res 2011, 93:842-851.
21. Taylor-Harding B., Orsulic S., Karlan B.Y., et al. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol 2010, 119:549-556.
22. Bouterfa H.L., Sattelmeyer V., Czub S., et al. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 2000, 20:2761-2771.
23. Denoylle C.H., Vasse M., Körner M., et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signalling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: in vitro study. Carcinogenesis 2001, 22:1139-1148.
24. DeClue J.E., Vass W.C., Papageorge A.G., et al. Inhibition of cell growth by lovastatin is independent of Ras function. Cancer Res 1991, 1:712-717.
25. Kubatka P., Kajo K., Žihlavniková K., et al. Immunohistochemical and histomorphological analysis of rat mammary tumors after simvastatin treatment. Neoplasma 2012, 59:516-523.
26. Narisawa T., Morotomi M., Fukaura Y., et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1996, 87:798-804.
27. Maltese W.A., Defendini R., Green R.A., et al. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase. J Clin Invest 1985, 76:1748-1754.
28. Bjorkhem-Bergman L., Acimovic J., Torndal U.B., et al. Lovastatin prevents carcinogenesis in a rat model for liver cancer: effects of ubiquinone supplementation. Anticancer Res 2010, 30:1105-1112.
29. Xia Z., Tan M.M., Wong W.W., et al. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukaemia cells. Leukaemia (Baltimore) 2001, 15:1398-1407.
30. Zhu Y., Casey P.J., Kumar A.P., Pervaiz S. Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Cell Death Dis 2013, 4:e568.
31. Marcuzzi A., Zanin V., Piscianz E., et al. Lovastatin-induced apoptosis is modulated by geranylgeraniol in a neuroblastoma cell line. Int J Dev Neurosci 2012, 30:451-456.
32. Dimitroulakos J., Nohynek D., Backway K.L., et al. Increased sensitivity of acute myeloid leukaemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999, 93:1308-1318.
33. Marcelli M., Cunningham G.R., Haidacher S.J., et al. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 1998, 58:76-83.
34. Wang I.K., Lin-Shiau S.Y., Lin J.K. Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol Toxicol 2000, 86:83-91.
35. Shellman Y.G., Ribbble D., Miller L., et al. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res 2005, 15:83-89.
36. Chapman-Shimshoni D., Yuklea M., Radnay J., et al. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003, 31:779-783.
37. Aprigliano I., Dudas J., Ramadori G., Saile B. Atorvastatin induces apoptosis by a caspase-9 dependent pathway: an in vitro study on activated rat hepatic stellate cells. Liver Int 2008, 28:546-557.
38. Kubatka P., Stollárová N., Škarda J., et al. Preventive effects of fluvastatin in rat mammary carcinogenesis. Eur J Cancer Prev 2013, 22:352-357.
39. Yu X., Pan Y., Ma H., Li W. Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells. Oncol Res 2013, 20:351-357.
40. Kubatka P., Žihlavniková K., Solár P., et al. Anti-tumor effects of atorvastatin in the chemoprevention of rat mammary carcinogenesis. Biologia 2011, 66:727-734.
41. Zanfardino M., Spampanato C., De Cicco R., et al. Simvastatin reduces melanoma progression in a murine model. Int J Oncol 2013, 43:1763-1770.
42. Infante E., Heasman S.J., Ridley A.J. Statins inhibit T-acute lymphoblastic leukaemia cell adhesion and migration through Rap1b. J Leukoc Biol 2011, 89:577-586.
43. Shiota M., Hikita Y., Kawamoto Y., et al. Pravastatin-induced proangiogenic effects depend upon extracellular FGF-2. J Cell Mol Med 2012, 16:2001-2009.
44. Coimbra M., Banciu M., Fens M.H., et al. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. J Control Release 2010, 148:303-310.
45. Weis M., Heeschen C., Glassford A.J., Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 2002, 105:739-745.
46. Feleszko W., Balkowiec E.Z., Sieberth E., et al. Lovastatin and tumor necrosis factor exhibit potentiated anti-tumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 1999, 81:560-567.
47. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000, 6:1004-1010.
48. Park H.J., Kong D., Iruela-Arispe L., et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002, 91:143-150.
49. Nubel T., Dippold W., Kleinert H., et al. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J 2004, 18:140-142.
50. Andrade V.L., do Valle I.B., Sandrim V.C. Simvastatin therapy decreases MMP-9 levels in obese women. J Clin Pharmacol 2013, 53:1072-1077.
51. Kang S., Kim E.S., Moon A. Simvastatin and lovastatin inhibit breast cell invasion induced by H-ras. Oncol Rep 2009, 21:1317-1322.
52. Glynn S.A., O'Sullivan D., Eustace A.J., et al. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer 2008, 8:9.
53. Brown M., Hart C., Tawadros T., et al. The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer 2012, 106:1689-1696.
54. Sokalska A., Cress A., Bruner/Tran K.L., et al. Simvastatin decreases invasiveness of human endometrial stromal cells. Biol Reprod 2012, 87:2.
55. Kusama T., Mukai M., Iwasaki T., et al. Inhibition of epidermal growth factor/induced RhoA translocation and invasion of human pancreatic cancer cells by 3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res 2001, 61:4885-4891.
56. Mehta N., Hordines J., Sykes D., et al. Low density lipoproteins and lovastatin modulate the organ-specific transendothelial migration of primary and metastatic human colon adenocarcinoma cell lines in vitro. Clin Exp Metastasis 1998, 16:587-594.
57. Assmus B., Urbich C., Aicher A., et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003, 92:1049-1055.
58. Lee M.H., Yee Cho S., Han Y.M. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation. Stem Cell 2007, 25:1654-1660.
59. Krutá M., Bálek L., Hejnová R., et al. Decrease in abundance of apurinic/apyrimidinic endonuclease causes failure of base excision repair in culture-adapted human embryonic stem cells. Stem Cells 2013, 31:693-702.
60. Gauthaman K., Manasi N., Bongso A. Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br J Pharmacol 2009, 157:962-973.
61. Zhang Z., Li S., Cui M., et al. Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. Basic Res Cardiol 2013, 108:333.
62. Kodach L.L., Jacobs R.J., Voorneveld P.W., et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 2011, 60:1544-1553.
63. MacDonald J.S., Gerson R.J., Kornbrust D.J., et al. Preclinical evaluation of lovastatin. Am J Cardiol 1998, 62:16J-27J.
64. Smith P.F., Grossman S.J., Gerson R.J., et al. Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat. Toxicol Pathol 1991, 19:197-205.
65. Tatsuta M., Iishi H., Baba M., et al. Suppression by pravastatin, an inhibitor of p21ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Br J Cancer 1998, 77:581-587.
66. Kim W., Yoon J.H., Kim J.R., et al. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. Cancer Chemother Pharmacol 2009, 64:497-507.
67. Narisawa T., Fukaura Y., Terada K., et al. Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994, 15:2045-2048.
68. Wang C.Y., Shui H.A., Chang T.C. Lovastatin-induced differentiation of anaplastic thyroid cancer cells via flotillin-1 as a downstream mediator. Endocr J 2010, 57:S478-S479.
69. Huang E.H., Johnson L.A., Eaton K., et al. Atorvastatin induces apoptosis in vitro and slows growth of tumor xenografts but not polyp formation in MIN mice. Dig Dis Sci 2010, 55:3086-3094.
70. Teraoka N., Mutoh M., Takasu S., et al. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prev Res (Phila) 2011, 4:445-453.
71. Lee J., Lee I., Han B., et al. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 2011, 103:674-688.
72. Zheng X., Cui X.X., Gao Z., et al. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res (Phila) 2010, 3:114-124.
73. Kubatka P., Žihlavniková K., Kajo K., et al. Rosuvastatin in the chemoprevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats. Acta Vet (Beograd) 2011, 61:445-460.
74. Lubet R.A., Boring D., Steele V.E., et al. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis. Cancer Prev Res 2009, 2:161-167.
75. Vinayak S., Schwartz E.J., Jensen K., et al. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat 2013, 142:389-398.
76. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. N Engl J Med 2013, 367:1792-1802.
77. Yu O., Eberg M., Benayoun S., et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 2013, 32:5-11.
78. Jacobs E.J., Newton C.C., Thun M.J., Gapstur S.M. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 2011, 71:1763-1771.
79. Rosch P.J., McCully K. Statin use and reduced cancer-related mortality. N Engl J Med 2013, 368:576.
80. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
81. Strandberg T.E., Pyörälä K., Cook T.J., et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004, 364:771-777.
82. Benn M., Tybjaerg-Hansen A., Stender S., et al. Low-density lipoprotein cholesterol and the risk of cancer: a Mendelian randomisation study. J Natl Cancer Inst 2011, 103:508-519.
83. Emberson J.R., Kearney P.M., Blackwell L., et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE 2012, 7:e29849-e29859.
84. Bonovas S., Filioussi K., Tsavaris N., Sitaras N.M. Use of statins and breast cancer: a meta-analysis of seven randomised clinical trials and nine observational studies. J Clin Oncol 2005, 23:8606-8612.
85. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
86. Dawwas M.F. Statin use and reduced cancer-related mortality. N Engl J Med 2013, 368:574-575.
87. Ravnskov U., McCully K.S., Rosch P.J. The statin-low cholesterol-cancer conundrum. QJM 2012, 105:383-388.
88. Williams R.R., Sorlie P.D., Feinleib M., et al. Cancer incidence by levels of cholesterol. J Am Med Assoc 1981, 245:247-252.
89. Schuit A.J., Van Dijk C.E., Dekker J.M., et al. Inverse association between serum total cholesterol and cancer mortality in Dutch civil servants. Am J Epidemiol 1993, 137:966-976.
90. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
91. Solomon K.R., Freeman M.R. The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am 2011, 38:243-259.
92. Jacobs J.M., Cohen A., Ein-Mor E., Stessman J. Cholesterol, statins, and longevity from age 70 to 90 years. J Am Med Dir Assoc 2013, 14:883-888.
93. Damrot J., Nubel T., Epe B., et al. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anti-cancer drugs doxorubicin and etoposide. Br J Pharmacol 2006, 149:988-997.
94. An Y., Xin H., Yan W., Zhou X. Amelioration of cisplatin-induced nephrotoxicity by pravastatin in mice. Exp Toxicol Pathol 2011, 63:215-219.
95. Singh S., Singh A.G., Singh P.P., et al. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013, 11:620-629.
96. Beales I.L.P., Vardi I., Dearman L., et al. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study. Dis Esophagus 2013, 26:838-846.
97. Alexandre L., Clark A.B., Bhutta H.Y., et al. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis. Gastroenterology 2014, 146:661-668.
98. Alexandre L., Clark A.B., Cheong E., et al. Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma. Alim Pharmacol Ther 2012, 36:301-311.
99. Singh P.P., Roberts L.R., Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014, 11:45-54.
100. Singh S., Singh P.P., Singh A.G., et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013, 144:323-332.
101. Tsan Y.T., Lee C.H., Ho W.C., et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013, 31:1514-1521.
102. Pradelli D., Soranna D., Scotti L., et al. Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev 2013, 22:229-234.
103. Lonardo A., Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol 2012, 27:1654-1664.
104. Yilmaz Y., Colak Y., Kurt R., et al. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back. Tumori 2013, 99:10-16.
105. Aleksandrova K., Boeing H., Jenab M., et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res (Phila) 2011, 4:1873-1883.
106. Stocks T., Lukanova A., Bjorge T., et al. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer 2011, 117:2398-2407.
107. Eddi R., Karki A., Shah A., et al. Association of type 2 diabetes and colon adenomas. J Gastrointest Cancer 2012, 43:87-92.
108. Esteve E., Ricart W., Fernandez-Real J.M. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 2005, 24:16-31.
109. Hutcheson R., Rocic P. The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration. Exp Diabetes Res 2012, 2012:271028.
110. Avramoglu R.K., Basciano H., Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta 2006, 368:1-19.
111. Agnoli C., Grioni S., Sieri S., et al. Colorectal cancer risk and dyslipidemia: a case-cohort study nested in an Italian multicentre cohort. Cancer Epidemiol 2014, 38:144-151.
112. Yang Y., Mauldin P.D., Ebeling M., et al. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer 2013, 119:1512-1520.
113. Liu Y., Tang W., Wang J., et al. Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Cause Control 2014, 25:237-249.
114. Mace A.G., Gantt G.A., Skacel M., et al. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum 2013, 56:1217-1227.
115. Lytras T., Nikolopoulos G., Bonovas S. Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies. World J Gastroenterol 2014, 20:1858-1870.
116. Ng K., Ogino S., Meyerhardt J.A., et al. A relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 2011, 103:1540-1551.
117. Lee J.E., Baba Y., Ng K., et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res 2011, 4:1808-1815.
118. Limburg P.J., Mahoney M.R., Ziegler K.L.A., et al. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res 2011, 4:259-269.
119. Menter D.G., Ramsauer V.P., Harirforoosh S., et al. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS ONE 2011, 6:e28813.
120. Pereira M.A., Warner B.M., Knobloch T.J., et al. Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin. Int J Cancer 2012, 131:1277-1286.
121. Asakura K., Izumi Y., Yamamoto M., et al. The cytostatic effects of lovastatin on ACC-MESO-1 cells. J Surg Res 2011, 170:E197-E209.
122. Suh N., Reddy B.S., DeCastro A., et al. Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/beta-catenin/cyclin D1 signaling pathway in rats. Cancer Prev Res 2011, 4:1895-1902.
123. Teraoka N., Mutoh M., Takasu S., et al. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prev Res 2011, 4:445-453.
124. Feng L., Yap K.B., Kua E.H., Ng T.P. Statin use and depressive symptoms in a prospective study of community-living older persons. Pharmacoepidemiol Drug Saf 2010, 19:942-948.
125. Yang C.C., Jick S.S., Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003, 163:1926-1932.
126. Li G., Higdon R., Kukull W.A., et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004, 63:1624-1628.
127. Macedo A.F., Taylor F.C., Casas J.P., et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014, 12:51-151.
128. Rzouq F.S., Volk M.L., Hatoum H.H., et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci 2010, 340:89-93.
129. Thavendiranathan P., Bagai A., Brookhart M.A., et al. Primary prevention of cardiovascular diseases with statin therapy - a meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166:2307-2313.
130. Silva M., Matthews M.L., Jarvis C., et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007, 29:253-260.
131. de Denus S., Spinler S.A., Miller K., et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004, 24:584-591.
132. Smeeth L., Douglas I., Hall A.J., et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009, 67:99-109.
133. Hippisley-Cox J., Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. Br Med J 2010, 340:c2197.
134. Eslami L., Merat S., Malekzadeh R., et al. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2013, 12:CD008623.
135. Younossi Z.M., Reyes M.J., Mishra A., et al. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Alim Pharmacol Ther 2014, 39:3-14.